• 1. Evidence of field induced slow magnetic relaxation in cis-[Co(hfac)2(H2O)2] exhibiting tri-axial anisotropy with a negative axial component?
  Denis V. Korchagin,Elena A. Yureva,Alexander V. Akimov,Eugenii Ya. Misochko,Gennady V. Shilov,Artem D. Talantsev,Roman B. Morgunov,Alexander A. Shakin,Sergey M. Aldoshin,Boris S. Tsukerblat Dalton Trans., 2017,46, 7540-7548
• 2. Empowering microfluidics by micro-3D printing and solution-based mineral coating?
  Hongxia Li,Aikifa Raza,Qiaoyu Ge,Jin-You Lu,TieJun Zhang Soft Matter, 2020,16, 6841-6849
• 3. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 4. Fe/S-Catalyzed synthesis of 2-benzoylbenzoxazoles and 2-quinolylbenzoxazoles via redox condensation of o-nitrophenols with acetophenones and methylquinolines?
  Thi Thu Tram Nguyen,Thanh Binh Nguyen Org. Biomol. Chem., 2021,19, 6015-6020
• 5. Evolution of hierarchical porous structures in supramolecular guest–host hydrogels?
  Christopher B. Rodell,Christopher B. Highley,Minna H. Chen,Neville N. Dusaj,Chao Wang,Lin Han,Jason A. Burdick Soft Matter, 2016,12, 7839-7847

• Solvents and Organic Chemicals Organic Compounds Benzenoids Phenol ethers Anisoles

Introduction to (2S)-2-[(3-Methoxyphenoxy)methyl]morpholine Hydrochloride (CAS No. 55253-30-0)

(2S)-2-[(3-Methoxyphenoxy)methyl]morpholine hydrochloride, with the CAS number 55253-30-0, is a significant compound in the field of pharmaceutical chemistry. This compound has garnered considerable attention due to its unique structural properties and potential applications in drug development. The morpholine moiety, combined with the (2S) configuration, contributes to its distinct pharmacological profile, making it a subject of interest for researchers exploring novel therapeutic agents.

The< strong>3-methoxyphenoxy group in the molecular structure imparts specific interactions with biological targets, which is a critical factor in determining its efficacy and selectivity. This feature has been extensively studied in recent years, particularly in the context of developing drugs that target central nervous system disorders. The hydrochloride salt form enhances the solubility and bioavailability of the compound, making it more suitable for pharmaceutical formulations.

In recent years, there has been a surge in research focused on identifying and developing new compounds that can modulate neurotransmitter systems. (2S)-2-[(3-Methoxyphenoxy)methyl]morpholine hydrochloride has emerged as a promising candidate in this area. Its ability to interact with specific receptors and enzymes has been investigated in several preclinical studies. These studies have revealed potential applications in treating conditions such as depression, anxiety, and neurodegenerative diseases.

The stereochemistry of the compound, particularly the (2S) configuration of the morpholine ring, plays a crucial role in its pharmacological activity. This chirality ensures that the compound interacts selectively with biological targets, minimizing off-target effects. The importance of stereochemistry in drug design cannot be overstated, as it often determines the therapeutic efficacy and safety of a drug.

Recent advancements in computational chemistry have enabled researchers to predict the binding affinity and interaction patterns of (2S)-2-[(3-Methoxyphenoxy)methyl]morpholine hydrochloride with various biological targets. These computational studies have provided valuable insights into its mechanism of action and have helped guide further experimental investigations. By leveraging these computational tools, scientists can accelerate the drug discovery process and identify potential lead compounds more efficiently.

The< strong>3-methoxyphenoxy group is particularly interesting from a structural perspective. This moiety can engage in multiple types of interactions with biological targets, including hydrogen bonding, hydrophobic interactions, and π-stacking. These interactions contribute to the compound's binding affinity and selectivity, making it a versatile tool for drug development. Researchers have explored various derivatives of this group to optimize its pharmacological properties further.

In addition to its potential applications in central nervous system disorders, (2S)-2-[(3-Methoxyphenoxy)methyl]morpholine hydrochloride has also been investigated for its anti-inflammatory properties. In preclinical studies, this compound has shown promise in reducing inflammation by modulating key signaling pathways involved in immune responses. These findings suggest that it may have therapeutic potential in conditions such as rheumatoid arthritis and inflammatory bowel disease.

The synthesis of (2S)-2-[(3-Methoxyphenoxy)methyl]morpholine hydrochloride involves several key steps that require precise control over reaction conditions. The stereochemical integrity of the morpholine ring must be maintained throughout the synthesis process to ensure the desired pharmacological activity. Advanced synthetic techniques, such as asymmetric catalysis and chiral resolution methods, have been employed to achieve high enantiomeric purity.

The development of novel pharmaceuticals often involves a multidisciplinary approach, combining expertise from chemistry, biology, pharmacology, and computational science. (2S)-2-[(3-Methoxyphenoxy)methyl]morpholine hydrochloride exemplifies this collaborative effort, as it represents the culmination of years of research by scientists from various fields. The continued investigation of this compound holds promise for future breakthroughs in drug development.

As our understanding of biological systems continues to evolve, so does our ability to design targeted therapeutics. (2S)-2-[(3-Methoxyphenoxy)methyl]morpholine hydrochloride is a testament to this progress, showcasing how structural modifications can lead to novel pharmacological effects. The ongoing research into this compound underscores the importance of innovation and collaboration in advancing pharmaceutical science.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)